002435 Changjiang Runfa Health Industry
- 0.92
- -0.05-5.15%
Changjiang Runfa Health Industry News
Express News | Special treat Changkang: The closing price of the company's stocks has fallen below 1 yuan for the first time, which may entail the risk of being delisted.
Express News | ST Changkang: The closing price of the company's stocks has fallen below 1 yuan for the first time, with the risk of possible delisting.
ST Changkang (002435.SZ) stock price changes There are no important matters that should be disclosed and no important matters have been disclosed
ST Changkang (002435.SZ) issued an announcement. The company's stock trading price was traded for three consecutive trading days (2024...
The ST sector continued to adjust, and nearly 40 ST shares, including ST Changkang, ST Sansheng, ST Bailey, ST Communications, ST Dongshi, and ST Xinlun, were blocked and suspended.
The ST sector continued to adjust, and nearly 40 ST shares, including ST Changkang, ST Sansheng, ST Bailey, ST Communications, ST Dongshi, and ST Xinlun, were blocked and suspended.
ST Changkang (002435) announced on the evening of May 10 that the company received the Jiangsu Securities Regulatory Bureau's “Decision on Ordering Corrective Measures against Changjiang Runfa Health Industry Co., Ltd. and Changjiang Runfa Group Co., Ltd.
ST Changkang (002435) announced on the evening of May 10 that the company received the Jiangsu Securities Regulatory Bureau's “Decision on Ordering Corrective Measures against Changjiang Runfa Health Industry Co., Ltd. and Changjiang Runfa Group Co., Ltd.” It was investigated that Runfa Group, the controlling shareholder of the company, and its related parties had unoperated acts of usurping the company's capital in the early stages. The Jiangsu Securities Regulatory Bureau decided to take corrective administrative supervision measures against the company and Runfa Group and record them in the securities and futures market integrity file.
Express News | ST Changkang: Received an order from the Jiangsu Securities Regulatory Bureau to take corrective measures and decided that there is a risk of delisting
ST Changkang (002435.SZ): The company has no immunotherapy related products or programs
Gelonghui, May 10 | ST Changkang (002435.SZ) said on the investor interactive platform that the company has no products or projects related to immunotherapy.
The ST sector continued to decline. *ST Nongshang, *ST Baoli fell to a halt by 20cm, *ST Shimao, *ST Hetai, ST Changkang, ST Xinlun, etc., and nearly 50 ST stocks were blocked and stopped.
The ST sector continued to decline. *ST Nongshang, *ST Baoli fell to a halt by 20cm, *ST Shimao, *ST Hetai, ST Changkang, ST Xinlun, etc., and nearly 50 ST stocks were blocked and stopped.
ST Changkang (002435.SZ): Unstructured field of synthetic biology
Gelonghui, May 9 | ST Changkang (002435.SZ) said on the investor interactive platform that the company is not currently in the field of synthetic biology.
Express News | ST Changkang: There have been no major changes in the company's business situation or internal and external business environment recently
Changjiang Health (002435.SZ) announced its first quarter results, with a net loss of 1.00673 million yuan, a year-on-year profit to loss
Changjiang Health (002435.SZ) released its report for the first quarter of 2024. The company's revenue was 660 million...
Express News | Changjiang Health: The company and controlling shareholders received a notice from the Securities Regulatory Commission to file a case
Changjiang Health (002435.SZ): Hunan Yongxing's shareholding ratio fell to 4.98%
Gelonghui, March 28, 丨 Changjiang Health (002435.SZ) announced that the company recently received the “Notice Letter on the Progress of the Share Reduction Plan” and “Simplified Equity Change Report” from Yongxing, Hunan. Hunan Yongxing reduced its holdings of Yangtze River Health shares by 300,000 shares (0.02% of the company's total share capital) through bulk transactions. After this change in equity, the shares held by Hunan Yongxing were reduced to 61,500,000 shares, and the shareholding ratio dropped to 4.98%. Hunan Yongxing is no longer a shareholder holding 5% or more of the company's shares.
Changjiang Health (002435.SZ): CH2101, an innovative antiviral oral small molecule drug developed, has entered the clinical phase II research stage
Gelonghui March 28 丨 Some investors asked Changjiang Health (002435.SZ) on the investor interactive platform, “How is your company currently developing anti-COVID-19 drugs?” The company replied that CH2101, an innovative antiviral oral small molecule drug developed by the company, has entered phase II clinical research.
Changjiang Health (002435.SZ): Ningbo Ningju's shareholding ratio dropped to 4.9999%
Gelonghui, March 4, 丨 Changjiang Health (002435.SZ) announced that the company recently received the “Notice of Shareholding Reduction” and “Simplified Equity Change Report” from Ningbo Ningju. Ningbo Ningju reduced its holdings of Changjiang Health Co., Ltd. by 12,236,300 shares (0.99% of the company's total share capital) through bulk transactions. After this change in equity, the shares held by Ningbo Ningju were reduced to 61,799,100 shares, and the shareholding ratio dropped to 4.9999%. Ningbo Ningju is no longer a shareholder holding more than 5% of the company's shares.
Changjiang Health (002435.SZ): The company is currently not developing diet pills
Gelonghui, Feb. 21丨Changjiang Health (002435.SZ) said on the investor interactive platform that the company is currently not developing diet pills.
Changjiang Health (002435.SZ): Its pharmaceutical division includes metformin hydrochloride extended-release tablets to treat diabetes, simvastatin tablets to treat coronary heart disease, Zidan active blood capsules, etc.
Gelonghui, Feb. 20 | Changjiang Health (002435.SZ) said on the investor interactive platform that the company's pharmaceutical division includes metformin hydrochloride extended-release tablets to treat diabetes, simvastatin tablets to treat coronary heart disease, Zidan blood boosting capsules, etc.
Changjiang Health (002435.SZ): The company has not implemented blockchain technology yet
Gelonghui, January 30丨Changjiang Health (002435.SZ) said on the investor interactive platform that the company has not implemented blockchain technology yet and will thoroughly understand blockchain technology in the future in line with the company's development needs.
CRO and innovative drug sectors strengthen, Hongbo Pharmaceutical rises and stops 20CM
Gelonghui January 25 | Hongbo Pharmaceutical rose and stopped 20CM, Changjiang Health shook up and down, and Wanbang Pharmaceutical, Xuantai Pharmaceutical, Chengdu Pioneer, and Gibel followed suit. According to the news, the General Department of the State Drug Administration issued a public request for opinions on the “Notice on Optimizing the Application for Marketing Registration of Overseas Produced Drugs Already Marketed in China and Transferring Domestically Produced Drugs to Domestically Produced Drugs”. Among them, it was mentioned that the State Drug Administration included in the scope of priority review and approval for drug marketing registration applications transferred to domestically produced chemicals and biological products from original research.
Changjiang Health (002435.SZ): Suzhou Yihe Health Management Co., Ltd., a wholly-owned subsidiary, has begun to build a high-quality nursing community
Gelonghui, January 17丨Changjiang Health (002435.SZ) said on the investor interactive platform that the company participated in investing in Wuxi Yihe Hospital in 2022. The hospital is a specialized hospital focusing on the health of women, children, and the elderly, built according to level-3 hospital standards. The hospital's subsidiary Wuxi Yihe Nursing Home is an age-friendly medical institution in Jiangsu Province and a district-level Samsung pension institution that provides “medical treatment, rehabilitation, nursing, institutional care, home care” five-in-one management service. A total of 500 beds have been opened and a special nursing area for Alzheimer's conditions has been set up. In addition, Suzhou Yihe Health, a wholly-owned subsidiary of the company
Analysis
Price Target
No Data
